EIF4E and hematologic disorder: Knocking down eIF4E ameliorated tumorigenesis as well, and consequently, drugs targeting eIF4E to inhibit mRNA translation have been heavily tested in clinical trials for hematologic malignancies (Rinker-Schaeffer et al., 1993; Blagden and Willis 2011).